专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明公开

US20240165256A1 METHODS FOR INCREASING EFFICACY OF IMMUNOCONJUGATES TARGETING ADAM9 FOR THE TREATMENT OF CANCER 审中-公开
公开(公告)号：US20240165256A1
公开(公告)日：2024-05-23
申请号：US18280896
申请日：2022-03-07
申请人： IMMUNOGEN, INC. , MACROGENICS, INC.
发明人： Eric Henry Westin , Callum Sloss , Krystal Marie Watkins , Deryk T. Loo , Juniper A. Scribner , Francine Zhifen Chen
IPC分类号： A61K47/68 , A61P35/00 , G01N33/574
CPC分类号： A61K47/6851 , A61K47/68033 , A61K47/6889 , A61P35/00 , G01N33/57484 , G01N2333/96486
摘要： The present disclosure provides methods of treating cancer in a subject who has an increased level of ADAM9 expression. The method comprises administering to the subject a therapeutically effective amount of an anti-ADAM9 immunoconjugate. Also provided is a method of increasing the efficacy of cancer treatment with an anti-ADAM9 immunoconjugate in a subject who has an increased level of ADAM9 expression.

2. 发明申请

US20210388102A1 IMMUNOCONJUGATES TARGETING ADAM9 AND METHODS OF USE THEREOF 有权
公开(公告)号：US20210388102A1
公开(公告)日：2021-12-16
申请号：US16469494
申请日：2017-12-21
申请人： IMMUNOGEN, INC. , MACROGENICS, INC.
发明人： Stuart William Hicks , Nicholas C. Yoder , Bhaswati Barat , Ezio Bonvini , Gundo Diedrich , Leslie S. Johnson , Deryk Loo , Juniper A. Scribner
IPC分类号： C07K16/28 , A61K47/68 , C07K16/30 , A61P35/00
摘要： The present invention is directed to immunoconjugates comprising an antibody or fragment thereof capable of specifically binding to “Disintegrin and Metalloproteinase Domain-containing Protein 9” (“ADAM9”) conjugated to at least one pharmacological agent. The invention particularly concerns such immunoconjugates that are cross-reactive with human ADAM9 and the ADAM9 of a non-human primate (e.g., a cynomolgus monkey). The invention additionally pertains to all such immunoconjugates that comprise a Light Chain Variable (VL) Domain and/or a Heavy Chain Variable (VH) Domain that has been humanized and/or deimmunized so as to exhibit reduced immunogenicity upon administration of such immunoconjugate to a recipient subject. The invention is also directed to pharmaceutical compositions that contain any of such immunoconjugates, and to methods involving the use of any of such immunoconjugates in the treatment of cancer and other diseases and conditions.

3. 发明申请

US20210275685A1 IMMUNOCONJUGATES TARGETING ADAM9 AND METHODS OF USE THEREOF 有权
公开(公告)号：US20210275685A1
公开(公告)日：2021-09-09
申请号：US17255064
申请日：2019-06-25
申请人： IMMUNOGEN, INC. , MACROGENICS, INC.
发明人： Stuart William Hicks , Nicholas C. Yoder , Bhaswati Barat , Ezio Bonvini , Gundo Diedrich , Leslie S. Johnson , Deryk Loo , Juniper A. Scribner
IPC分类号： A61K47/68 , C07K16/40 , A61K31/5365 , A61K47/22 , A61P35/00
摘要： The present invention is directed to immunoconjugates comprising an antibody or fragment thereof capable of specifically binding to “Disintegrin and Metalloproteinase Domain- containing Protein 9” (“ADAM9”) conjugated to at least one maytansinoid compound. The invention particularly concerns such immunoconjugates that are cross-reactive with human ADAM9 and the ADAM9 of a non-human primate (e.g., a cynomolgus monkey). The invention additionally pertains to all such immunoconjugates that comprise a Light Chain Variable (VL) Domain and/or a Heavy Chain Variable (VH) Domain that has been humanized and/or deimmunized so as to exhibit reduced immunogenicity upon administration of such immunoconjugate to a recipient subject. The invention is also directed to pharmaceutical compositions that contain any of such immunoconjugates, and to methods involving the use of any of such immunoconjugates in the treatment of cancer and other diseases and conditions.

4. 发明申请

US20210171641A1 NOVEL B7-H3 BINDING MOLECULES, ANTIBODY DRUG CONJUGATES THEREOF AND METHODS OF USE THEREOF 有权
公开(公告)号：US20210171641A1
公开(公告)日：2021-06-10
申请号：US17124972
申请日：2020-12-17
申请人： MacroGenics, Inc.
发明人： Deryk T. LOO , Ling Huang , Leslie S. Johnson , Thomas Son , Juniper A. Scribner , Ezio Bonvini
IPC分类号： C07K16/28 , A61K47/68 , A61K39/395 , A61P35/00
摘要： The present invention is directed to novel B7-H3-binding molecules capable of binding to human and non-human B7-H3, and in particular to such molecules that are cross-reactive with B7-H3 of a non-human primate (e.g., a cynomolgus monkey). The invention additionally pertains to B7-H3-binding molecules that comprise Variable Light Chain and/or Variable Heavy Chain (VH) Domains that have been humanized and/or deimmunized so as to exhibit a reduced immunogenicity upon administration to recipient subjects. The invention particularly pertains to bispecific, trispecific or multispecific B7-H3-binding molecules, including bispecific diabodies, BiTEs, bispecific antibodies, trivalent binding molecules, etc. that comprise: (i) such B7-H3-binding Variable Domains and (ii) a domain capable of binding to an epitope of a molecule present on the surface of an effector cell. The invention is also directed to pharmaceutical compositions that contain any of such B7-H3-binding molecules, and to methods involving the use of any of such B7-H3-binding molecules in the treatment of cancer and other diseases and conditions. The invention also particularly pertains to a molecule that comprises the human B7-H3 binding domain of a humanized anti-human B7-H3 antibody conjugated to at least one drug moiety (a “B7-H3-ADC”). The invention is also directed to pharmaceutical compositions that contain such B7-H3-ADCs, and to methods involving the use of any of such B7-H3-ADCs in the treatment of cancer and other diseases and conditions.

5. 发明授权

US11242402B2 ADAM9-binding molecules, and methods of use thereof 有权
公开(公告)号：US11242402B2
公开(公告)日：2022-02-08
申请号：US16471449
申请日：2017-12-21
申请人： MacroGenics, Inc.
发明人： Deryk T. Loo , Juniper A. Scribner , Bhaswati Barat , Gundo Diedrich , Leslie S. Johnson , Ezio Bonvini
IPC分类号： C07K16/28 , C07K16/30 , A61K39/395 , C07K16/18 , C07K16/46 , A61K39/00
摘要： The present invention is directed to molecules, such as monospecific antibodies and bispecific, trispecific or multispecific binding molecules, including diabodies, BITE® molecules, and antibodies that are capable of specifically binding to “Disintegrin and Metalloproteinase Domain-containing Protein 9” (“ADAM9”). The invention particularly concerns such binding molecules that are capable of exhibiting high affinity binding to human and non-human ADAM9. The invention further particularly relates to such molecules that are thereby cross-reactive with human ADAM9 and the ADAM9 of a non-human primate (e.g., a cynomolgus monkey). The invention additionally pertains to all such ADAM9-binding molecules that comprise a Light Chain Variable (VL) Domain and/or a Heavy Chain Variable (VH) Domain that has been humanized and/or deimmunized so as to exhibit reduced immunogenicity upon administration of such ADAM9-binding molecule to a recipient subject. The invention is also directed to pharmaceutical compositions that contain any of such ADAM9-binding molecules, and to methods involving the use of any of such ADAM9-binding molecules in the treatment of cancer and other diseases and conditions.

6. 发明申请

US20190382502A1 ADAM9-Binding Molecules, and Methods of Use Thereof 审中-公开
公开(公告)号：US20190382502A1
公开(公告)日：2019-12-19
申请号：US16471449
申请日：2017-12-21
申请人： MacroGenics, Inc.
发明人： Deryk T. Loo , Juniper A. Scribner , Bhaswati Barat , Gundo Diedrich , Leslie S. Johnson , Ezio Bonvini
IPC分类号： C07K16/28 , C07K16/18 , C07K16/46
摘要： The present invention is directed to molecules, such as monospecific antibodies and bispecific, trispecific or multispecific binding molecules, including diabodies, BiTEs, and antibodies that are capable of specifically binding to “Disintegrin and Metalloproteinase Domain-containing Protein 9” (“ADAM9”). The invention particularly concerns such binding molecules that are capable of exhibiting high affinity binding to human and non-human ADAM9. The invention further particularly relates to such molecules that are thereby cross-reactive with human ADAM9 and the ADAM9 of a non-human primate (e.g., a cynomolgus monkey). The invention additionally pertains to all such ADAM9-binding molecules that comprise a Light Chain Variable (VL) Domain and/or a Heavy Chain Variable (VH) Domain that has been humanized and/or deimmunized so as to exhibit reduced immunogenicity upon administration of such ADAM9-binding molecule to a recipient subject. The invention is also directed to pharmaceutical compositions that contain any of such ADAM9-binding molecules, and to methods involving the use of any of such ADAM9-binding molecules in the treatment of cancer and other diseases and conditions.

7. 发明授权

US11591400B2 B7-H3 directed antibody drug conjugates 有权
公开(公告)号：US11591400B2
公开(公告)日：2023-02-28
申请号：US17124972
申请日：2020-12-17
申请人： MacroGenics, Inc.
发明人： Deryk T. Loo , Ling Huang , Leslie S. Johnson , Thomas Son , Juniper A. Scribner , Ezio Bonvini
IPC分类号： C07K16/28 , A61K47/68 , A61K39/395 , A61P35/00 , A61K39/00
摘要： The present invention is directed to novel B7-H3-binding molecules capable of binding to human and non-human B7-H3, and in particular to such molecules that are cross-reactive with B7-H3 of a non-human primate (e.g., a cynomolgus monkey). The invention additionally pertains to B7-H3-binding molecules that comprise Variable Light Chain and/or Variable Heavy Chain (VH) Domains that have been humanized and/or deimmunized so as to exhibit a reduced immunogenicity upon administration to recipient subjects. The invention particularly pertains to bispecific, trispecific or multispecific B7-H3-binding molecules, including bispecific diabodies, BiTEs, bispecific antibodies, trivalent binding molecules, etc. that comprise: (i) such B7-H3-binding Variable Domains and (ii) a domain capable of binding to an epitope of a molecule present on the surface of an effector cell. The invention is also directed to pharmaceutical compositions that contain any of such B7-H3-binding molecules, and to methods involving the use of any of such B7-H3-binding molecules in the treatment of cancer and other diseases and conditions. The invention also particularly pertains to a molecule that comprises the human B7-H3 binding domain of a humanized anti-human B7-H3 antibody conjugated to at least one drug moiety (a “B7-H3-ADC”). The invention is also directed to pharmaceutical compositions that contain such B7-H3-ADCs, and to methods involving the use of any of such B7-H3-ADCs in the treatment of cancer and other diseases and conditions.

8. 发明申请

US20220324995A1 ADAM9-Binding Molecules, and Methods of Use Thereof 有权
公开(公告)号：US20220324995A1
公开(公告)日：2022-10-13
申请号：US17553941
申请日：2021-12-17
申请人： MacroGenics, Inc.
发明人： Deryk T. Loo , Juniper A. Scribner , Bhaswati Barat , Gundo Diedrich , Leslie S. Johnson , Ezio Bonvini
IPC分类号： C07K16/28 , C07K16/18 , C07K16/46
摘要： The present invention is directed to molecules, such as monospecific antibodies and bispecific, trispecific or multispecific binding molecules, including diabodies, BITE® molecules, and antibodies that are capable of specifically binding to “Disintegrin and Metalloproteinase Domain-containing Protein 9” (“ADAM9”). The invention particularly concerns such binding molecules that are capable of exhibiting high affinity binding to human and non-human ADAM9. The invention further particularly relates to such molecules that are thereby cross-reactive with human ADAM9 and the ADAM9 of a non-human primate (e.g., a cynomolgus monkey). The invention additionally pertains to all such ADAM9-binding molecules that comprise a Light Chain Variable (VL) Domain and/or a Heavy Chain Variable (VH) Domain that has been humanized and/or deimmunized so as to exhibit reduced immunogenicity upon administration of such ADAM9-binding molecule to a recipient subject. The invention is also directed to pharmaceutical compositions that contain any of such ADAM9-binding molecules, and to methods involving the use of any of such ADAM9-binding molecules in the treatment of cancer and other diseases and conditions.

9. 发明授权

US10961311B2 B7-H3 binding molecules, antibody drug conjugates thereof and methods of use thereof 有权
公开(公告)号：US10961311B2
公开(公告)日：2021-03-30
申请号：US16092740
申请日：2017-04-13
申请人： MacroGenics, Inc.
发明人： Deryk T. Loo , Ling Huang , Leslie S. Johnson , Thomas Son , Juniper A. Scribner , Ezio Bonvini
IPC分类号： C07K16/28 , A61K47/68 , A61K39/395 , A61P35/00 , A61K39/00
摘要： The present invention is directed to novel B7-H3-binding molecules capable of binding to human and non-human B7-H3, and in particular to such molecules that are cross-reactive with B7-H3 of a non-human primate (e.g., a cynomolgus monkey). The invention additionally pertains to B7-H3-binding molecules that comprise Variable Light Chain and/or Variable Heavy Chain (VH) Domains that have been humanized and/or deimmunized so as to exhibit a reduced immunogenicity upon administration to recipient subjects. The invention particularly pertains to bispecific, trispecific or multispecific B7-H3-binding molecules, including bispecific diabodies, BiTEs, bispecific antibodies, trivalent binding molecules, etc. that comprise: (i) such B7-H3-binding Variable Domains and (ii) a domain capable of binding to an epitope of a molecule present on the surface of an effector cell. The invention is also directed to pharmaceutical compositions that contain any of such B7-H3-binding molecules, and to methods involving the use of any of such B7-H3-binding molecules in the treatment of cancer and other diseases and conditions. The invention also particularly pertains to a molecule that comprises the human B7-H3 binding domain of a humanized anti-human B7-H3 antibody conjugated to at least one drug moiety (a “B7-H3-ADC”). The invention is also directed to pharmaceutical compositions that contain such B7-H3-ADCs, and to methods involving the use of any of such B7-H3-ADCs in the treatment of cancer and other diseases and conditions.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式